Preoxygenation With Optiflow™ - the Effect of Speech on Lung Oxygenation.

University Hospital Southampton NHS Foundation Trust

Status: Completed

Conditions: Unrecognized Condition

Treatments: Device: Optiflow

Study type: Interventional

Funder types: Other

Identifiers

NCT03766646

RHM CR10369

Details and patient eligibility

About

If a patient speaks during the process of preoxygenation with high-flow nasal oxygen via the Optiflow™ system, is the efficacy reduced as measured by end-tidal lung oxygen content?

Full description

This is a randomised controlled trial on 34 patients undergoing routine elective surgery at the Princess Anne Hospital, Southampton. The study will take place from September 2018 to January 2019 and involve preoxygenating all participants for three minutes using the Optiflow™ device. During this time, participants will be instructed to either read aloud a standardised text or to breathe through their nose with a closed mouth. At the end of 3 minutes, the primary outcome, ETO2, will be measured and recorded.

Enrollment: 34 patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI 18-35, ASA category 1 or 2

Exclusion criteria

• Inability to read/ follow instructions, Heavily sedated

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

34 participants in 2 patient groups

Speech

Experimental group

Description:

Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.

Treatment:

Device: Optiflow

Non-speech

Active Comparator group

Description:

Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.

Treatment:

Device: Optiflow